Week in Review: Porton Fine Chemicals Buys Dongbang Pharma

Porton Fine Chemicals of Chongqing will pay $42 million to acquire Jiangxi Dongbang Pharma, combining their CMO API assets; Shanghai Pharma will form a $16 million on-line drug distribution JV with Zhongxie Pharma; WuXi PharmaTech will build a new facility in Philadelphia to manufacture viral vector cell therapy products; GlaxoSmithKline announced plans for a larger Asia headquarters in Singapore; Green Cross, a South Korean biopharma, signed a MOU to build a cell therapy manufacturing and distributing center in China's Guizhou Province; Luqa Pharma of Hong Kong began a China launch of Ialuxid®, a non-antibiotic antimicrobial gel made by BMG Pharma of Italy; Hua Medicine of Shanghai filed an IND to begin US clinical trials of its novel type 2 diabetes treatment; and Steve Yang, Executive Vice-President and COO of WuXi PharmaTech spoke about China's drug development ecosystem as the 2015 edition of the ChinaBio® Partnering Forum draws near. More details.... Stock Symbols: (SHE: 300363) (SHA: 601607; HK: 2607) (NYSE: WX) (NYSE: GSK) Share this with colleagues: // //